Zoetis stock
Price history
−29.56% over the period1 year: from $118.80 (November 17, 2025) to $83.69 (November 17, 2026), −29.56%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 17, 2026 | $83.69 |
| October 30, 2026 | $79.72 |
| September 30, 2026 | $69.83 |
| August 31, 2026 | $77.10 |
| July 31, 2026 | $77.29 |
| June 30, 2026 | $71.86 |
| May 29, 2026 | $77.69 |
| April 30, 2026 | $114.97 |
| March 31, 2026 | $118.21 |
| February 27, 2026 | $131.10 |
| January 30, 2026 | $124.82 |
| December 31, 2025 | $125.82 |
| November 28, 2025 | $128.18 |
| November 17, 2025 | $118.80 |
At a glance
The company
Discover, develop, manufacture and commercialize medicines, vaccines, diagnostics and precision animal health solutions for companion and livestock animals
Latest results
Quarter to September 30, 2026 · EPS $1.75 (estimate $1.51)
TickerLandia's take on Zoetis
- Cheaper than usual relative to earnings: P/E on the latest fiscal year 14 vs a median of 36 over its last 10 fiscal years.
- Cheaper than similar companies: trailing 12-month P/E 14 vs 28 (−49%) in a group of 9.
- Strong point: Profitability (86/100 in its group). Weak point: Growth (31/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−36.99% from the 52-week high
Analysts · 16 analysts
Average target$89.69+7.44% vs. price
Buy 6 · Hold 10 · Sell 0 · Buy
TickerLandia Fingerprint: Zoetis
Compared with similar companies: very high profitability.
Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 883 North American stocks.
Pricelow38
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 14.1 13 Forward P/E 13.1 13 EV/EBITDA 10.4 21 Price/book 10.3 86 Price/sales 3.57 55 Profitabilityvery high86
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 71.6% 62 Operating margin 37.9% 93 Net margin 26.4% 80 ROE 57.6% 99 ROA 14.9% 96 Earnings stabilityhigh77
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 0.9% 91 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Growthlow31
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) −1.30% 9 Earnings growth (year over year) −11.80% 43 Average revenue growth (3 years) +5.42% 41 Financial strengthlow37
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 1.72 34 Interest coverage 16.3 53 Debt/equitycounts in reverse: lower means more financial strength 2.80 4 Current ratio 2.35 59 Dividendaverage55
How much it returns to shareholders, and for how long.
Metric Value Position in group Payout ratio 35.7% 48 Dividend yield 2.5% 68 Consecutive dividend years at least 14 years 47 Market momentumaverage48
How the stock has moved compared with the market.
Metric Value Position in group 1-year return −29.73% 8 Distance from 200-day average −8.34% 26 Relative strength (3 months) +19.47% 89 Relative strength (6 months) +12.35% 66 Riskhigh60
How much the price swings.
Metric Value Position in group Volatility (60 days) 35.0% 51 Beta (1 year) 0.61 46 Maximum drawdown (12 months) 47.3% 82
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Zoetis is cheaper than in the past and cheaper than similar companies
On the latest fiscal year's earnings (2025), Zoetis's P/E today is 13.9, below the median of its last 10 fiscal years (35.8; between 20.9 and 57.1 from 2016 to 2025). Zoetis's P/E (trailing 12 months): 14.1, −49% against the median of a group of 9 similar companies (27.6).
Compared with 9 similar companies
| Metric | Zoetis | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 14.1 | Low | |
| Forward P/E | 13.1 | Low | |
| Operating margin | 37.9% | High | |
| ROE | 57.6% | High | |
| Debt/equity | 2.80 | High |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Zoetis. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$2.39B
Latest quarter · Q3 2026
Net income
$591M
Latest quarter · Q3 2026
Quarterly net margin
24.7%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $33.92B
- P/E
- 14.1
- EPS
- $5.94
- Volume
- 3.35M
- Daily trading
- €341.63M
- Dividend yield
- 2.54%
- Last ex-dividend on October 30, 2026
How Zoetis is changing
All resultsRevenue grew 7.2% a year on average over the last 5 years
Operating margin rose from 36.3% to 38.3%
Free cash flow equal to 83% of net income
Returns
Zoetis returns with dividends
$1,000 invested in Zoetis 5 years ago, on November 17, 2021, would be worth $401 today with dividends reinvested: −59.88% in total, −16.70% per year. On price alone it would be $377 (−62.28%).
| Period | Zoetis | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +5.15% | −3.17% | $1,051 |
| 6 months | +12.48% | +0.11% | $1,125 |
| Year to date | −33.49% | +8.34% | $665 |
| 1 year | −27.98% | +11.15% | $720 |
| 3 years | −49.91% | +64.30% | $501 |
| 5 years | −59.88% | +58.18% | $401 |
| 10 years | +86.49% | +239.10% | $1,865 |
Over the last 6 months it has done better than 45% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment
The chart in detail
Zoetis: technical analysis
Zoetis shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 66.2% below its all-time closing high ($247.03, December 29, 2021).
- Trend
- No clear trend
- RSI (14 sessions)
- 57
- Between 30 and 70
- vs 200-session average
- −8.34%
Support and resistance
Price areas where Zoetis has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$123.87+48.38%2 touches, last on April 20, 2026
- Resistance$119.50+43.15%2 touches, last on February 12, 2026
- Resistance$115.42+38.26%2 touches, last on December 9, 2025
- Last price$83.48
- Support$82.54−1.13%3 touches, last on October 22, 2026
- Support$78.07−6.47%6 touches, last on November 6, 2026
- Support$73.47−12.00%2 touches, last on July 23, 2026
Volatility and risk
Over the last year it has moved less than the S&P 500.
- Beta (1 year) vs S&P 500
- 0.61
- Volatility (60 sessions, annualised)
- 35.0%
- Largest fall in the last year
- −47.29%
Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Zoetis: seasonality
Average monthly price change over 14 years
Over the last 14 years, the strongest month for Zoetis has been November: +3.88% on average, positive in 9 years out of 13. The weakest has been March: −1.96% on average, positive in 6 years out of 14.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | −1.50% | −0.70% | 6 of 13 |
| February | +1.80% | +0.91% | 8 of 13 |
| March | −1.96% | −0.24% | 6 of 14 |
| April | +1.25% | +0.56% | 7 of 14 |
| May | +0.19% | +1.14% | 9 of 14 |
| June | +0.72% | +0.36% | 9 of 14 |
| July | +3.51% | +2.92% | 12 of 14 |
| August | +1.13% | +1.27% | 10 of 14 |
| September | −1.38% | −0.19% | 7 of 14 |
| October | +0.23% | +0.33% | 8 of 14 |
| November | +3.88% | +2.70% | 9 of 13 |
| December | +1.63% | +2.61% | 7 of 13 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Zoetis and its competitors
Based in Parsippany, New Jersey, Zoetis was founded in 1952 and works in animal health, covering the discovery, development, manufacture and sale of medicines, vaccines, diagnostic products, biodevices, genetic tests and precision animal health solutions. Its products are aimed mainly at companion animals such as dogs, cats and horses, and at livestock including cattle, swine, poultry, fish and sheep, and are marketed to veterinarians, livestock producers and pet owners.
- Headquarters
- Parsippany, United States
- Employees
- 14,500
- Founded
- 1952
- Chief executive
- Kristin Peck
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| ZoetisZTS | $33.92B | 37.9% | 14.1 | +12.48% |
| United TherapeuticsUTHR | $25.04B | 39.4% | 22.2 | +2.73% |
| ViatrisVTRS | $23.58B | — | — | +24.09% |
| Teva Pharmaceutical IndustriesTEVA | $49.67B | 19.8% | 99.0 | +24.29% |
| Neurocrine BiosciencesNBIX | $16.73B | 26.6% | 24.5 | +4.73% |
| Hims & Hers HealthHIMS | $4.13B | -6.4% | — | −29.94% |
Same industry or related industries, similar size. Compare Zoetis with its competitors · Full profile
